For the 35th prioritisation (March 2018), eight drugs were filtered out of 404 identified and were sent to prioritisation. Of these, six drugs were ranked as 'highly relevant' by the expert panel, one as 'relevant' and one as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.